DOCSLIB.ORG

1 Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-P27

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-P27 Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Targeting TAZ-driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis He Shen 1, Nuo Yang 2, Alexander Truskinovsky 3, Yanmin Chen 1, Ashley L. Mussell 1, Norma J. Nowak4, Lester Kobzik5, Costa Frangou 5* and Jianmin Zhang 1* 1. Department of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263 2. Department of Anesthesiology, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, The State University of New York, NY 14214 3. Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263 4. Department of Biochemistry, Jacobs School of Medicine & Biomedical Sciences, University at Buffalo, The State University of New York, NY 14214 5. Harvard TH Chan School of Public Health, Molecular and Integrative Physiological Sciences, 665 Huntington Avenue, Boston, MA 02115 Running Title: TAZ-induced BLBC Tumor Maintenance Through SKP2-p27 Key words: TAZ, SKP2, breast cancer, cell cycle, oncogene dependence, tumor maintenance. 1 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Additional information: Financial support: National Cancer Institute (NCI) R01 CA207504 and the American Cancer Society Research Scholar Grant RSG-14-214-01-TBE (to J.Z.). Correspondence: * Dr. Costa Frangou, Harvard TH Chan School of Public Health, Molecular and Integrative Physiological Sciences, 665 Huntington Avenue, Boston, MA 02115 [email protected] * Dr. Jianmin Zhang, Department of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263 [email protected] The authors declare no potential conflicts of interest. Word count: 5935 Number of figures: 6 2 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Deregulated expression of the transcriptional co-activator with PDZ-binding motif (WWTR1/TAZ) is a common feature of basal-like breast cancer (BLBC). Yet, how oncogenic TAZ regulates cell cycle progression and proliferation in breast cancer remains poorly understood, and whether TAZ is required for tumor maintenance has not been established. Here, using an integrative oncogenomic approach, TAZ-dependent cellular programs essential for tumor growth and progression were identified. Significantly, TAZ-driven tumor cells required sustained TAZ expression, given that its withdrawal impaired both genesis and maintenance of solid tumors. Moreover, temporal inhibition of TAZ diminished the metastatic burden in established macroscopic pulmonary metastases. Mechanistic investigation revealed that TAZ controls distinct gene profiles that determine cancer cell fate through cell cycle networks, including a specific, causal role for S-phase kinase-associated protein 2 (SKP2) in mediating the neoplastic state. Together, this study elucidates the molecular events that underpin the role of TAZ in BLBC and link to SKP2, a convergent communication node for multiple cancer signaling pathways, as a key downstream effector molecule. Implications: Understanding the molecular role of TAZ and its link to SKP2, a signaling convergent point and key regulator in BLBC, represents an important step toward the identification of novel therapeutic targets for TAZ-dependent breast cancer. 3 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction Breast cancer (BC) is a multifaceted disease with distinct histopathologic features, genetic and genomic variability, and prognostic outcomes. Breast tumor heterogeneity is dynamic and evolves unpredictably during disease progression, creating considerable variability within primary tumors and metastases (1). However, BC can be classified into at least four major molecular subtypes based on gene expression programmes: luminal A, luminal B, HER2-enriched, and basal-like (2). These subtypes exhibit important differences in risk factors, response to treatment, likelihood of disease progression, and propensity to metastasize to multiple organs, including bones, lungs, and liver (3). Basal-like BCs (BLBCs) are especially associated with an aggressive clinical history, early recurrence, distant metastasis, and reduced survival rates in patients. BLBCs lack oestrogen (ER), progesterone (PR) and HER2 expression (4). These characteristics make BLBCs challenging to treat, as they do not respond to endocrine treatments or targeted therapies, and treatment options are restricted to conventional chemotherapy. Despite extensive efforts to characterize the BLBC subtype, the oncogenic drivers of BLBC remain elusive (5). Several genomic and genetic studies have identified multiple candidate oncogenic alterations in BLBC (6). These include genes associated with signal transduction, angiogenesis, the cell cycle and proliferation, cell survival, DNA replication and recombination, motility and invasion (7). For example, PTEN loss, PI3K/AKT pathway activation, and TP53 mutations are frequently observed in BLBCs (8, 9). But widespread chromosomal instability is typical in BLBC (10), making it difficult to distinguish genes driving cancer development from those playing a bystander role. 4 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The blockade of transcription factor interactions can be especially attractive in targeting cellular pathways that promote oncogenic transformation and typically involve many signaling proteins that ultimately converge on a much smaller set of oncogenic transcription factors. Recently, we and others reported that protein expression of the Hippo transducer transcriptional co-activator with PDZ-binding motif (TAZ) is associated with a decreased survival rate and shorter time to relapse in BLBC patients (11, 12). The oncogenic activity of TAZ involves the regulation of diverse signal transduction pathways that direct such processes as proliferation, migration, and resistance to apoptosis, albeit through poorly characterized gene expression programmes (13). Ectopic expression of TAZ in human cell and transgenic murine tissues results in their oncogenic transformation (11, 14). However, whether oncogenic TAZ is required for the maintenance of BLBC has not been established. To test whether TAZ is necessary for maintaining as well as developing a cancer, we generated a transplant-based model of BLBC in which constitutively active TAZ expression is controlled in a doxycycline (dox)-dependent manner. We exploited this ability to precisely control the timing of TAZ expression during tumorigenesis and metastasis, which allowed us to examine the consequence of sustained TAZ activity on the maintenance of the transformed state in a relevant experimental setting. Using this system, we found that TAZ is not only a driver of BLBC progression and a novel prognostic factor but is also required for the maintenance of tumors and already established metastases. Importantly, this finding credentials TAZ as a legitimate BC therapeutic target. Furthermore, through iterative rounds of hypothesis generation and testing, we demonstrated that TAZ drives an SKP2-regulated cell cycle programme 5 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. involving genes linked to tumorigenic potential and poor prognosis in BC. As a result, our work provides biological insight and proof-of-concept evidence for targeting TAZ- regulated genes that support tumour maintenance to identify novel treatments for BC. 6 Downloaded from mcr.aacrjournals.org on September 25, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 20, 2018; DOI: 10.1158/1541-7786.MCR-18-0332 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Materials and methods Cell culture: MCF10A, HMEC, T47D, BT474, MDA-MB-453, MDA-MB-468, ZR751, BT549, CAL120, CAL51, MDA-MB-231, MDA-MB-361, MDA-MB-435, SUM159, HCC38, HCC1143, HCC1937 cell culture was performed as previously described (12). MDA-MB-231, T47D, MDA-MB453, BT-474, HCC38 HCC1143 and HCC1937 cells were purchased from American Type Culture Collection (ATCC, VA); MCF10A and HMEC were obtained from Dr. Joan Brugge, Harvard Medical School; CAL51, CAL120 and SUM159 were obtained
Load more

Recommended publications
  • Feeling the Force: Role of Amotl2 in Normal Development and Cancer
    Department of Oncology and Pathology Karolinska Institute, Stockholm, Sweden FEELING THE FORCE: ROLE OF AMOTL2 IN NORMAL DEVELOPMENT AND CANCER Aravindh Subramani Stockholm 2019 All previously published papers were reproduced with permission from the publisher. Front cover was modified from ©Renaud Chabrier and illustrated by Yu-Hsuan Hsu Published by Karolinska Institute. Printed by: US-AB Stockholm © Aravindh Subramani, 2019 ISBN 978-91-7831-426-3 Feeling the force: Role of AmotL2 in normal development and cancer. THESIS FOR DOCTORAL DEGREE (Ph.D.) J3:04, Torsten N Wiesel, U410033310, Bioclinicum, Karolinska University Hospital, Solna, Stockholm Friday, April 12th, 2019 at 13:00 By Aravindh Subramani Principal Supervisor: Opponent: Professor. Lars Holmgren Professor. Marius Sudol Karolinska Institute National University of Singapore Department of Oncology-Pathology Mechanobiology Institute (MBI) Co-supervisor(s): Examination Board: Docent. Jonas Fuxe Docent. Kaisa Lehti Karolinska Institute Karolinska institute Department of Microbiology, Tumor and Cell Department of Microbiology and Tumor Biology Biology (MTC) center (MTC) Associate Professor. Johan Hartman Docent. Ingvar Ferby Karolinska Institute Uppsala University Department of Oncology-Pathology Department of Medical Biochemistry and Microbiology Docent. Mimmi Shoshan Karolinska Institute Department of Oncology-Pathology To my mom and dad “Real knowledge is to know the extent of one's ignorance.” (Confucius) ABSTRACT Cells that fabricate the body, dwell in a very heterogeneous environment. Self-organization of individual cells into complex tissues and organs at the time of growth and revival is brought about by the combinatory action of biomechanical and biochemical signaling processes. Tissue generation and functional organogenesis, requires distinct cell types to unite together and associate with their corresponding microenvironment in a spatio-temporal manner.
    [Show full text]
  • The VE-Cadherin/Amotl2 Mechanosensory Pathway Suppresses Aortic InAmmation and the Formation of Abdominal Aortic Aneurysms
    The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang Karolinska Institute Evelyn Hutterer Karolinska Institute Sara Hultin Karolinska Institute Otto Bergman Karolinska Institute Maria Forteza Karolinska Institute Zorana Andonovic Karolinska Institute Daniel Ketelhuth Karolinska University Hospital, Stockholm, Sweden Joy Roy Karolinska Institute Per Eriksson Karolinska Institute Lars Holmgren ( [email protected] ) Karolinska Institute Article Keywords: arterial endothelial cells (ECs), vascular disease, abdominal aortic aneurysms Posted Date: June 15th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-600069/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang1, Evelyn Hutterer1, Sara Hultin1, Otto Bergman2, Maria J. Forteza2, Zorana Andonovic1, Daniel F.J. Ketelhuth2,3, Joy Roy4, Per Eriksson2 and Lars Holmgren1*. 1Department of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden. 2Department of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 3Department of Cardiovascular and Renal Research, Institutet of Molecular Medicine, Univ. of Southern Denmark, Odense, Denmark 4Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm,
    [Show full text]
  • Integrated Epigenome, Exome and Transcriptome Analyses Reveal Molecular Subtypes and Homeotic Transformation in Uterine Fibroids
    bioRxiv preprint doi: https://doi.org/10.1101/452342; this version posted October 29, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Integrated epigenome, exome and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Jitu W. George1*, Huihui Fan2*, Benjamin K. Johnson2, Anindita Chatterjee1, Amanda L. Patterson1, Julie Koeman4, Marie Adams4, Zachary B. Madaj3, David W. Chesla5, Erica E. Marsh6, Timothy J. Triche2, Hui Shen2#, Jose M. Teixeira1# 1Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA 2Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA 3 Bioinformatics and Biostatistics Core, Van Andel Research Institute, Grand Rapids, MI, USA 4Genomics Core, Van Andel Research Institute, Grand Rapids, MI, USA 5Spectrum Health Universal Biorepository, Spectrum Health System, Grand Rapids, MI, USA 6Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA #Corresponding Authors: Hui Shen, PhD, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503. email [email protected] Jose M. Teixeira, PhD, Michigan State University, 400 Monroe Ave NW, Grand Rapids, MI 49503. email: [email protected] Funding: This work was supported by grant HD072489 from the National Institute of Child Health and Development to J.M.T. The authors do not have any conflicts of interest to declare. bioRxiv preprint doi: https://doi.org/10.1101/452342; this version posted October 29, 2018.
    [Show full text]
  • AMOTL1 Enhances YAP1 Stability and Promotes YAP1-Driven Gastric Oncogenesis
    Oncogene (2020) 39:4375–4389 https://doi.org/10.1038/s41388-020-1293-5 ARTICLE AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis 1,2,3 1,2,3 1 1,2,3 2 1 1 Yuhang Zhou ● Jinglin Zhang ● Hui Li ● Tingting Huang ● Chi Chun Wong ● Feng Wu ● Man Wu ● 4 5 6 2,7 1,3 1,3 Nuoqing Weng ● Liping Liu ● Alfred S. L. Cheng ● Jun Yu ● Nathalie Wong ● Kwok Wai Lo ● 1 1,2,3 1,2,3 Patrick M. K. Tang ● Wei Kang ● Ka Fai To Received: 20 January 2020 / Revised: 31 March 2020 / Accepted: 1 April 2020 / Published online: 20 April 2020 © The Author(s) 2020. This article is published with open access Abstract Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic downstream transcription, such as CTGF and c-Myc. How YAP1 is protected in the cytoplasm from ubiquitin-mediated degradation remains elusive. In this study, a member of Angiomotin (Motin) family, AMOTL1 (Angiomotin Like 1), was screened out as the only one to promote YAP1 nuclear accumulation by several clinical cohorts, which was further confirmed by the cellular functional assays. The interaction fl 1234567890();,: 1234567890();,: between YAP1 and AMOTL1 was suggested by co-immunoprecipitation and immuno uorescent staining. The clinical significance of the AMOTL1–YAP1–CTGF axis in gastric cancer (GC) was analyzed by multiple clinical cohorts. Moreover, the therapeutic effect of targeting the oncogenic axis was appraised by drug-sensitivity tests and xenograft- formation assays.
    [Show full text]
  • Identification and Characterization of a Novel Tight Junction-Associated Family of Proteins That Interacts with a WW Domain of MAGI-1
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1745 (2005) 131 – 144 http://www.elsevier.com/locate/bba Identification and characterization of a novel tight junction-associated family of proteins that interacts with a WW domain of MAGI-1 Kevin M. Patrie* Department of Internal Medicine, University of Michigan, 1580 MSRB II, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0676, USA Received 18 October 2004; received in revised form 24 May 2005; accepted 25 May 2005 Available online 15 June 2005 Abstract The membrane-associated guanylate kinase protein, MAGI-1, has been shown to be a component of epithelial tight junctions in both Madin–Darby canine kidney cells and in intestinal epithelium. Because we have previously observed MAGI-1 expression in glomerular visceral epithelial cells (podocytes) of the kidney, we screened a glomerular cDNA library to identify the potential binding partners of MAGI- 1 and isolated a partial cDNA encoding a novel protein. The partial cDNA exhibited a high degree of identity to an uncharacterized human cDNA clone, KIAA0989, which encodes a protein of 780 amino acids and contains a predicted coiled-coil domain in the middle of the protein. In vitro binding assays using the partial cDNA as a GST fusion protein confirm the binding to full-length MAGI-1 expressed in HEK293 cells, as well as endogenous MAGI-1, and also identified the first WW domain of MAGI-1 as the domain responsible for binding to this novel protein. Although a conventional PPxY binding motif for WW domains was not present in the partial cDNA clone, a variant WW binding motif was identified, LPxY, and found to be necessary for interacting with MAGI-1.
    [Show full text]
  • Expression of Periaxin (PRX) Specifically in the Human
    www.nature.com/scientificreports OPEN Expression of periaxin (PRX) specifcally in the human cerebrovascular system: PDZ Received: 6 November 2017 Accepted: 13 June 2018 domain-mediated strengthening Published: xx xx xxxx of endothelial barrier function Michael M. Wang1,2,3,4, Xiaojie Zhang1,2, Soo Jung Lee1,2, Snehaa Maripudi1,3, Richard F. Keep2,4,5, Allison M. Johnson4,6,7, Svetlana M. Stamatovic6,7 & Anuska V. Andjelkovic4,6,7 Regulation of cerebral endothelial cell function plays an essential role in changes in blood-brain barrier permeability. Proteins that are important for establishment of endothelial tight junctions have emerged as critical molecules, and PDZ domain containing-molecules are among the most important. We have discovered that the PDZ-domain containing protein periaxin (PRX) is expressed in human cerebral endothelial cells. Surprisingly, PRX protein is not detected in brain endothelium in other mammalian species, suggesting that it could confer human-specifc vascular properties. In endothelial cells, PRX is predominantly localized to the nucleus and not tight junctions. Transcriptome analysis shows that PRX expression suppresses, by at least 50%, a panel of infammatory markers, of which 70% are Type I interferon response genes; only four genes were signifcantly activated by PRX expression. When expressed in mouse endothelial cells, PRX strengthens barrier function, signifcantly increases transendothelial electrical resistance (~35%; p < 0.05), and reduces the permeability of a wide range of molecules. The PDZ domain of PRX is necessary and sufcient for its barrier enhancing properties, since a splice variant (S-PRX) that contains only the PDZ domain, also increases barrier function. PRX also attenuates the permeability enhancing efects of lipopolysaccharide.
    [Show full text]
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors
    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
    [Show full text]
  • UC San Diego Electronic Theses and Dissertations
    UC San Diego UC San Diego Electronic Theses and Dissertations Title Cardiac Stretch-Induced Transcriptomic Changes are Axis-Dependent Permalink https://escholarship.org/uc/item/7m04f0b0 Author Buchholz, Kyle Stephen Publication Date 2016 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA, SAN DIEGO Cardiac Stretch-Induced Transcriptomic Changes are Axis-Dependent A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioengineering by Kyle Stephen Buchholz Committee in Charge: Professor Jeffrey Omens, Chair Professor Andrew McCulloch, Co-Chair Professor Ju Chen Professor Karen Christman Professor Robert Ross Professor Alexander Zambon 2016 Copyright Kyle Stephen Buchholz, 2016 All rights reserved Signature Page The Dissertation of Kyle Stephen Buchholz is approved and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California, San Diego 2016 iii Dedication To my beautiful wife, Rhia. iv Table of Contents Signature Page ................................................................................................................... iii Dedication .......................................................................................................................... iv Table of Contents ................................................................................................................ v List of Figures ...................................................................................................................
    [Show full text]
  • Differentially Expressed Genes in Aneurysm Tissue Compared With
    On-line Table: Differentially expressed genes in aneurysm tissue compared with those in control tissue Fold False Discovery Direction of Gene Entrez Gene Name Function Change P Value Rate (q Value) Expression AADAC Arylacetamide deacetylase Positive regulation of triglyceride 4.46 1.33E-05 2.60E-04 Up-regulated catabolic process ABCA6 ATP-binding cassette, subfamily A (ABC1), Integral component of membrane 3.79 9.15E-14 8.88E-12 Up-regulated member 6 ABCC3 ATP-binding cassette, subfamily C (CFTR/MRP), ATPase activity, coupled to 6.63 1.21E-10 7.33E-09 Up-regulated member 3 transmembrane movement of substances ABI3 ABI family, member 3 Peptidyl-tyrosine phosphorylation 6.47 2.47E-05 4.56E-04 Up-regulated ACKR1 Atypical chemokine receptor 1 (Duffy blood G-protein–coupled receptor signaling 3.80 7.95E-10 4.18E-08 Up-regulated group) pathway ACKR2 Atypical chemokine receptor 2 G-protein–coupled receptor signaling 0.42 3.29E-04 4.41E-03 Down-regulated pathway ACSM1 Acyl-CoA synthetase medium-chain family Energy derivation by oxidation of 9.87 1.70E-08 6.52E-07 Up-regulated member 1 organic compounds ACTC1 Actin, ␣, cardiac muscle 1 Negative regulation of apoptotic 0.30 7.96E-06 1.65E-04 Down-regulated process ACTG2 Actin, ␥2, smooth muscle, enteric Blood microparticle 0.29 1.61E-16 2.36E-14 Down-regulated ADAM33 ADAM domain 33 Integral component of membrane 0.23 9.74E-09 3.95E-07 Down-regulated ADAM8 ADAM domain 8 Positive regulation of tumor necrosis 4.69 2.93E-04 4.01E-03 Up-regulated factor (ligand) superfamily member 11 production ADAMTS18
    [Show full text]
  • Table S1. 103 Ferroptosis-Related Genes Retrieved from the Genecards
    Table S1. 103 ferroptosis-related genes retrieved from the GeneCards. Gene Symbol Description Category GPX4 Glutathione Peroxidase 4 Protein Coding AIFM2 Apoptosis Inducing Factor Mitochondria Associated 2 Protein Coding TP53 Tumor Protein P53 Protein Coding ACSL4 Acyl-CoA Synthetase Long Chain Family Member 4 Protein Coding SLC7A11 Solute Carrier Family 7 Member 11 Protein Coding VDAC2 Voltage Dependent Anion Channel 2 Protein Coding VDAC3 Voltage Dependent Anion Channel 3 Protein Coding ATG5 Autophagy Related 5 Protein Coding ATG7 Autophagy Related 7 Protein Coding NCOA4 Nuclear Receptor Coactivator 4 Protein Coding HMOX1 Heme Oxygenase 1 Protein Coding SLC3A2 Solute Carrier Family 3 Member 2 Protein Coding ALOX15 Arachidonate 15-Lipoxygenase Protein Coding BECN1 Beclin 1 Protein Coding PRKAA1 Protein Kinase AMP-Activated Catalytic Subunit Alpha 1 Protein Coding SAT1 Spermidine/Spermine N1-Acetyltransferase 1 Protein Coding NF2 Neurofibromin 2 Protein Coding YAP1 Yes1 Associated Transcriptional Regulator Protein Coding FTH1 Ferritin Heavy Chain 1 Protein Coding TF Transferrin Protein Coding TFRC Transferrin Receptor Protein Coding FTL Ferritin Light Chain Protein Coding CYBB Cytochrome B-245 Beta Chain Protein Coding GSS Glutathione Synthetase Protein Coding CP Ceruloplasmin Protein Coding PRNP Prion Protein Protein Coding SLC11A2 Solute Carrier Family 11 Member 2 Protein Coding SLC40A1 Solute Carrier Family 40 Member 1 Protein Coding STEAP3 STEAP3 Metalloreductase Protein Coding ACSL1 Acyl-CoA Synthetase Long Chain Family Member 1 Protein
    [Show full text]
  • Deciphering the Genetics of Hereditary Non-Syndromic Colorectal Cancer
    European Journal of Human Genetics (2008) 16, 1477–1486 & 2008 Macmillan Publishers Limited All rights reserved 1018-4813/08 $32.00 www.nature.com/ejhg ARTICLE Deciphering the genetics of hereditary non-syndromic colorectal cancer Eli Papaemmanuil1,13, Luis Carvajal-Carmona2,13, Gabrielle S Sellick1,13, Zoe Kemp2,13, Emily Webb1, Sarah Spain2, Kate Sullivan1, Ella Barclay2, Steven Lubbe1, Emma Jaeger2, Jayaram Vijayakrishnan1, Peter Broderick1, Maggie Gorman2,3, Lynn Martin4,5, Anneke Lucassen6, D Timothy Bishop7, D Gareth Evans4, Eamonn R Maher5, Verena Steinke8, Nils Rahner8, Hans K Schackert9, Timm O Goecke10, Elke Holinski-Feder10, Peter Propping8, Tom Van Wezel11, Juul Wijnen11, Jean-Baptiste Cazier12, Huw Thomas3, Richard S Houlston*,1,14 and Ian Tomlinson*,2,14, The CORGI Consortium 1Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK; 2Molecular and Population Genetics Laboratory, Cancer Research UK, London, UK; 3Colorectal Cancer Unit, Cancer Research UK, St Mark’s Hospital, Harrow, UK; 4Medical Genetics, St Mary’s Hospital, Manchester, UK; 5Department of Medical and Molecular Genetics, University of Birmingham School of Medicine and West Midlands Genetics Service, Birmingham Women’s Hospital, Edgbaston, Birmingham, UK; 6Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK; 7Genetic Epidemiology Laboratory, Cancer Research UK, St James’s University Hospital, Leeds, UK; 8Institute of Human Genetics, University of Bonn, Bonn, Germany; 9Department of Surgical Research, Technische Universita¨t Dresden, Dresden, Germany; 10Institute of Human Genetics, University of Du¨sseldorf, Germany; 11Department of Pathology, Leiden Medical Centre, Leiden, The Netherlands; 12Bioinformatics and Biostatistics, London Research Institute, Cancer Research UK, London, UK Previously we have localized to chromosome 3q21–q24, a predisposition locus for colorectal cancer (CRC), through a genome-wide linkage screen (GWLS) of 69 families without familial adenomatous polyposis or hereditary non-polyposis CRC.
    [Show full text]
  • Identification of Novel Causative Genes for Colorectal Adenomatous Polyposis
    Identification of Novel Causative Genes for Colorectal Adenomatous Polyposis Dissertation zur Erlangung des Doktorgrades (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von Sukanya Horpaopan aus Nakhonsawan, Thailand Bonn, 2015 Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn Die vorliegende Arbeit wurde am Institut für Humangenetik der Rheinischen Friedrich‐Wilhelms‐Universität zu Bonn angefertigt. 1. Gutachter: Prof. Dr. Stefan Aretz 2. Gutachter: Prof. Dr. Michael Hoch Tag der Promotion: February 9, 2015 Erscheinungsjahr: 2015 TABLE OF CONTENTS Page Acknowledgements ................................................................................................................... VI Declaration ............................................................................................................................... VII List of abbreviations ................................................................................................................ VIII 1. INTRODUCTION .................................................................................................................... 1 2. BASIC PRINCIPLES .............................................................................................................. 3 2.1. Hereditary Colorectal Cancer ........................................................................................... 3 2.1.1. Differential diagnosis
    [Show full text]